Revaax Pharmaceuticals, LLC
Records under this name other than patents Revaax Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Revaax Pharmaceuticals, LLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,426,342 | Use of &bgr;-lactamase inhibitors as neuroprotectants Term ended Term ended Aug 16, 2020 · USPTO record | Term ended | Term ended Aug 16, 2020 | USPTO record |
| US 6,489,319 | Neurotherapeutic use of carboxypeptidase inhibitors Term ended Term ended Aug 16, 2020 · USPTO record | Term ended | Term ended Aug 16, 2020 | USPTO record |
| US 6,610,681 | Neurotherapeutic clavulanate composition and method Term ended Term ended Aug 16, 2020 · USPTO record | Term ended | Term ended Aug 16, 2020 | USPTO record |
| US 6,627,625 | Treatment of behavioral disorders with &bgr;-lactam compounds Term ended Ended no later than Aug 16, 2020 · USPTO record | Term ended | Ended no later than Aug 16, 2020 | USPTO record |
| US 7,998,991 | Neurotherapeutic treatment for sexual dysfunction Lapsed on the fee record Ended Aug 16, 2019 · USPTO record | Lapsed on the fee record | Ended Aug 16, 2019 | USPTO record |
| US 7,166,626 | Therapeutic treatment for sexual dysfunction Lapsed on the fee record Ended Jan 23, 2019 · USPTO record | Lapsed on the fee record | Ended Jan 23, 2019 | USPTO record |
| US 7,842,683 | Neurotherapeutic compositions and method Lapsed on the fee record Ended Nov 30, 2018 · USPTO record | Lapsed on the fee record | Ended Nov 30, 2018 | USPTO record |
| US 7,833,998 | Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions Lapsed on the fee record Ended Nov 16, 2018 · USPTO record | Lapsed on the fee record | Ended Nov 16, 2018 | USPTO record |